Press releases
- Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
- Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
- Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Key statistics
On Friday, Rocket Pharmaceuticals Inc (9IP1:FRA) closed at 21.30, 54.40% above the 52 week low of 13.80 set on Aug 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.30 |
---|---|
High | 21.30 |
Low | 21.30 |
Bid | 21.80 |
Offer | 21.85 |
Previous close | 20.86 |
Average volume | 1.00 |
---|---|
Shares outstanding | 90.50m |
Free float | 85.69m |
P/E (TTM) | -- |
Market cap | 2.12bn USD |
EPS (TTM) | -2.94 USD |
Data delayed at least 15 minutes, as of May 03 2024 07:05 BST.
More ▼